[1]
|
US-GAO (2008) GAO-08-980. United States Government Ac-countability Office: Indoor Mold: Better Coordination of Re-search on Health Effects and More Consistent Guidance Would Improve Federal Efforts, GAO, Washington DC.
|
[2]
|
WHO (2009) World Health Organization guidelines for indoor air quality: dampness and mould.
|
[3]
|
Shoemaker, R., Mark, L. and McMahon, S. (2010) Research Committee report on diag-nosis and treatment of chronic inflammatory response syndrome caused by exposure to the interior environment of wa-ter-damaged buildings: Expert treating physicians consensus. Policy holders of America, South Carolina, USA.
|
[4]
|
Shoemaker, R., House, D. and Ryan, J. (2010) De-fining the neurotoxin derived illness chronic ciguatera using markers of chronic systemic inflammatory disturbances: A case/control study. Neurotoxicology and Teratology, 32, 633-639. doi:10.1016/j.ntt.2010.05.007
|
[5]
|
Shoemaker, R. and Maizel, M. (2009) Innate immunity, MR spectroscopy, HLA DR, TGF beta-1, C4a, VIP and capillary hypoperfusion define acute and chronic illness acquired after exposure to water-damaged buildings. Heal thy Buildings IX, Syracuse.
|
[6]
|
Shoemaker, R. and Maizel, M. (2010) Exposure to water damaged buildings causes a readily identifiable chronic inflammatory response syndrome that is successfully treated by a sequential intervention protocol. Paper Presented at the International Mycological Congress 9, Ed inburgh.
|
[7]
|
Bourgault, S., Vaudry, D., Dejda, A., Doan, N.D., Vaudry, H. and Fournier, A. (2009) Pituitary adenylate cyclase activating polypeptide: Focus on structure-activity relationships of a neuroprotective peptide. Current Medicinal Chemistry, 16, 4462-4480.
doi:10.2174/092986709789712899
|
[8]
|
Gupta, V. and Ahsan, F. (2010) Inhalational therapy for pulmonary arterial hyperten-sion: current status and future prospects. Critical Reviews in Therapeutic Drug Carrier Systems, 27, 313-370.
doi:10.1615/CritRevTherDrugCarrierSyst.v27.i4.20
|
[9]
|
Delgado, M., Gomariz, R.P., Martinez, C., Abad, C. and Leceta, J. (2000) Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: Role in lethal endotoxic shock. European Journal of Immunology, 30, 3236-3246.
doi:10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L
|
[10]
|
Yu, X.J., Ren, X.H., Xu, Y.H., Chen, L.M., Zhou, C.L. and Li, C.Y. (2010) Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway. Neuropeptides, 44, 407-411. doi:10.1016/j.npep.2010.05.002
|
[11]
|
Francl, J.M., Kaur, G. and Glass, J.D. (2010) Regulation of vasoactive intes-tinal polypeptide release in the supra chiasmatic nucleus circadian clock. Neuroreport, 21, 1055 1059. doi:10.1097/WNR.0b013e32833fcba4
|
[12]
|
Chorny, A., Gon-zalez-Rey, E. and Delgado, M. (2006) Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation. Annals of the New York Academy of Sciences, 1088, 187-194. doi:10.1196/annals.1366.004
|
[13]
|
Gonzalez-Rey, E. and Del-gado, M. (2005) Role of vaso active intestinal peptide in in-flammation and autoimmunity. Current Opinion in Investiga-tional Drugs, 6, 1116 1123.
|
[14]
|
Delgado, M., Munoz-Elias, E.J., Gomariz, R.P. and Ganea, D. (1999) Vasoactive intestinal peptide and pitui tary adenylate cyclase-activating polypeptide enhance IL 10 production by murine macrophages: In vitro and in vivo studies. Journal of Immunology, 162, 1707-1716.
|
[15]
|
Delgado, M., Chorny, A., Gonzalez-Rey, E. and Ganea, D. (2005) Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. Journal of Leukocyte Biology, 78, 1327-1338. doi:10.1189/jlb.0605299
|
[16]
|
Delgado, M., Abad, C., Martinez, C., Leceta, J. and Go mariz, R.P. (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoim mune and inflammatory components of the disease. Na ture Medicine, 7, 563-568. doi:10.1038/87887
|
[17]
|
Leceta, J., Gomariz, R.P., Martinez, C., Carrion, M., Ar ranz, A. and Juarranz, Y. (2007) Vasoactive intestinal pep tide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation, 14, 134-138.
doi:10.1159/000110636
|
[18]
|
Prasse, A., Zissel, G., Lutzen N., Schupp, J., Schmiedlin, R., Gonzalez-Rey, E., Rensing-Ehl, A., Bacher, G, Cavalli, V., Bevec, D., Delgado, M. and Mul-ler-Quernheim, J. (2010) Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. American Journal of Respiratory and Critical, 182, 540-548.
doi:10.1164/rccm.200909-1451OC
|
[19]
|
Fabricius, D., O’Dorisio, M.S., Blackwell, S. and Jahrs dorfer, B. (2006) Human plasmacytoid dendritic cell function: Inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal pep tide. Journal of Immunology, 177, 5920-5927.
|